RemeGen Biosciences
Cai Guo has a diverse work experience in the field of biosciences and research. Their most recent role was as a Principal Scientist - CMC Upstream Development at RemeGen Biosciences, where they provided CMC regulatory strategies and guidance for comparability studies. Prior to that, they worked at Amgen as a Senior Scientist and Scientist in various roles, leading a team and producing therapeutic antibodies. They also conducted cell line development and utilized CRISPR editing tools. Cai Guo started their career as a Postdoctoral Fellow at the California Institute of Technology and City of Hope.
Cai Guo earned a PhD in Biology from the Irell & Manella Graduate School of Biological Sciences from 2003 to 2009. Prior to that, from 1999 to 2003, Cai Guo completed a BS in Biology at Nanjing University.
This person is not in the org chart
This person is not in any offices
RemeGen Biosciences
1 followers
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.